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Abstract
To survey healthcare-associated Clostridium difficile infection (HA-CDI) in a 900-bed tertiary-care hospital, we prospectively investigated
the epidemiology of CDI and distribution of PCR-ribotypes. From February 2009 through January 2010, all patients with HA-CDI were
enrolled. Epidemiological information and prescription records for antibiotics were collected. The C. difficile isolates were characterized
using reference strains and were tested for antibiotic susceptibility. During the survey, incidence of HA-CDI was 71.6 per 100 000
patient-days. In total, 140 C. difficile isolates were obtained from 166 patients with HA-CDI. The PCR-ribotyping yielded 38 distinct ribo-
types. The three most frequently found ribotypes made up 56.4% of all isolates; they comprised 37 isolates (26.4%) of PCR-ribotype
018, 22 (15.7%) of toxin A-negative PCR-ribotype 017, and 20 (14.3%) of PCR-ribotype 001. Clostridium difficile PCR-ribotype 018 was
present in all departments throughout the hospital during the 11 months, whereas ribotype 017 and ribotype 001 appeared mostly in
the pulmonary department. Hypervirulent C. difficile PCR-ribotype 027 was detected in 1 month on two wards. The incidence of CDI in
each department showed a seven-fold difference, which correlated significantly with the amount of prescribed clindamycin (R = 0.783,
p 0.013) or moxifloxacin (R = 0.733, p 0.025) in the departments. The rates of resistance of the three commonest ribotypes to clinda-
mycin and moxifloxacin were significantly higher than those of other strains (92.1% versus 38.2% and 89.5% versus 27.3%, respectively).
CDI is an important nosocomially acquired infection and this study emphasizes the importance of implementing country-wide surveil-
lance to detect and control CDI in Korea.
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Introduction
Clostridium difficile infection (CDI) is one of the most
important hospital infections, and during the past decade its
incidence has increased markedly worldwide [1]. Previous
exposure to antimicrobials, which can disrupt the normal
flora, is the main risk factor for CDI [1,2]. Clindamycin and
extended-spectrum cephalosporins are the antibiotics most
frequently implicated in CDI, whereas fluoroquinolones are
considered risk factors for CDI caused by the hypervirulent
BI/NAP1/027 (ribotype 027) strains that have become resis-
tant to newer fluoroquinolones (moxifloxacin, levofloxacin
and gatifloxacin) [2]. Additional risk factors for CDI include
age, underlying co-morbidities and hospital admission [3,4].
The incidence of CDI and its molecular epidemiology vary
depending on the country and over time. There has been a
well-documented increase in the incidence of CDI in North
America, largely attributed to the spread of ribotype 027
strains [1,5]. In Europe, the reported mean incidence of CDI
was 4.1 per 10 000 patient-days, ranging from 0 to 19.1 in
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different countries [6]. Finland had the highest incidence,
with two dominant PCR-ribotypes, 002 and 014. There are
few studies of the incidence of CDI in Asia. The reported
rate in Taiwan was 42.6 per 100 000 patient-days [7], and in
our hospital in Korea it was 71.6 [8]. In Japan the predomi-
nant ribotype of C. difficile was shown to account for up to
64% of all isolates, but type predominance changed over sev-
eral years [9,10]. One study reported ribotypes 002 and 014
to be dominant types [10].
Our objective was to examine the epidemiology of health-
care-associated CDI (HA-CDI) in our hospital. To this end
we analysed the distribution of the PCR-ribotypes found in
isolates from different hospital sites over 1 year, and we
studied the correlation between CDI incidence and antibiotic
prescriptions.
Materials and Methods
Patients and study design
The study was conducted at the Hanyang University Hospi-
tal, a 900-bed tertiary care facility in Seoul, South Korea. All
patients with diarrhoea whose stool samples were sent for
CDI testing between February 2009 and January 2010 were
included in the study. The study was approved by the Institu-
tional Review Board of Hanyang University Hospital (HYUH
IRB 2010-R-12).
Definitions and collection of data
A diagnosis of CDI was made when C. difficile isolates cultured
from stool samples contained toxin genes (tcdA, tcdB, cdtA or
cdtB) confirmed by multiplex PCR [11] or by a positive A & B
toxin assay (VIDAS C. difficile Toxin A & B; BioMe´rieux SA,
Marcy l’Etoile, France). The HA-CDI was diagnosed in patients
who developed diarrhoea at least 72 h after hospitalization or
within 2 months of the last discharge provided that they were
not residents in a long-term facility, and they tested positive
for CDI [12]. A large cluster was defined as more than ten iso-
lates with an identical ribotype during the year, and a small-
cluster, as four to nine isolates with identical ribotypes. The
diversity index was defined as the number of distinct ribotypes
divided by the total isolates, expressed as a percentage [13].
An outbreak was defined when the number of isolates with
the same ribotype in a month exceeded double the monthly
average. Incidence of CDI was defined as the number of cases
per 100 000 patient-days. Prescription records for clinda-
mycin, moxifloxacin, extended-spectrum cephalosporins, b-lac-
tam/b-lactamase inhibitors, fluoroquinolones and total
antibiotics were collected and converted to the number of
defined daily doses [14]. To compare the use of antibiotics, we
defined the prescription density of antibiotics (defined daily
doses per 1000 patient-days). The date of diagnosis, ward and
department of admission for each CDI patient were collected
as epidemiological data.
PCR-ribotyping of C. difficile isolates
Stools were cultured after alcohol shock [8] on cycloserine–
cefoxitin–fructose agar containing 0.1% taurocholic acid
(CCFA-TA, Oxoid Ltd., Basingstoke, UK) supplemented with
7% horse blood. The PCR-ribotyping was performed as
described elsewhere, with minor modifications [15,16]. After
electrophoresis of the amplified products, the clustering of
banding patterns was checked visually. Each unique pattern
was assigned its own ribotype code matched against available
reference strains according to international standards and
according to our system [17]. A PCR-ribotype code was
assigned to all PCR-ribotypes represented by more than
three isolates. Ribotype 027 (BI/NAP1/027), ATCC 43598
(ribotype 017) and strains from the ECDC-Brazier collection
were used for reference.
Antibiotic susceptibility
Susceptibility of the isolates to clindamycin and moxifloxacin
was measured by the E-test (AB-BIOdisc, Solna, Sweden) as
previously described [18]. Breakpoints for each compound
were defined by reference to the CLSI [19]. Clostridium diffi-
cile ATCC 700057 served as a quality control strain.
Statistical methods
SPSS version 18.0 for Windows (SPSS Inc., Chicago, IL, USA)
was used for statistical analysis. A Spearman’s rank correla-
tion analysis or the chi-square test was performed as appro-
priate. A p-value <0.05 in a two-tailed test was considered
statistically significant.
Results
Over 1 year, stool samples from patients with diarrhoea were
cultured for the presence of C. difficile. Out of 869 stool sam-
ples, 194 (22.3%) contained C. difficile with 54 distinct PCR-rib-
otypes (Fig. 1). Of the 194 isolates, 46 were non-toxigenic and
eight were derived from patients with community-onset CDI.
In total, 140 isolates of C. difficile were obtained from 166
patients with HA-CDI and included in the study.
The incidence of HA-CDI in our hospital was 71.6 per
100 000 patient-days or 64.9 per 10 000 admissions, as pre-
viously reported [8]. Table 1 shows the distribution of the
identified ribotypes. Among the 140 isolates there were 38
distinct ribotypes, and the diversity index was 27.1%. One
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hundred and sixteen of the 140 isolates (82.9%) shared a rib-
otype with an isolate from at least one other patient. Three
large-cluster isolates were identified, comprising 56.4% of all
isolates (79/140). Thirty-seven of these isolates (26.4%)
belonged to ribotype 018, 22 (15.7%) to ribotype 017 and
20 (14.3%) to ribotype 001. There were four small-cluster
isolates, corresponding to 15.0% of all isolates (21/140). The
small-cluster isolates were isolated from between four and
seven patients, and their ribotypes were 014, 112, 002 and
130. The cumulative percentage of large- and small-cluster
isolates was 71.4% (100/140) of the total number of isolates
(Table 1). Eleven isolates produced binary toxins (including
ribotypes 130, 122 and 027), and three ribotype 027.
Another quarter of all ribotypes (34/140 or 24.2%) were
found in only one (17.1%) or two (7.1%) isolates.
Incidence of CDI and the use of antibiotics
The incidence of CDI showed a seven-fold difference
between hospital departments, ranging from 26 to 186 per
100 000 patient-days (Table 2). We studied the correlation
between incidence and the amount of prescribed antibiotics
in each department. Use of clindamycin or moxifloxacin cor-
related significantly with the incidence of CDI in each depart-
ment: clindamycin (R = 0.783, p 0.013) and moxifloxacin
FIG. 1. The representative PCR-ribotype electrophoresis patterns from Clostridium difficile isolated from healthcare-associated C. difficile infection.
M, 1 kb ladder; lane 1 and 5, ribotypes of isolates 47 and 83 identical with PCR-ribotype 018; lane 2, ribotype of isolate 80 identical with PCR-
ribotype 017; lanes 3 and 4, ribotype of isolates 81 and 82 identical with PCR-ribotype 014; R1, reference strain (PCR-ribotype 017); R2, refer-
ence strain (PCR-ribotype 027); N, negative control.
TABLE 1. PCR-ribotypes of Clostridium difficile isolates from
healthcare-associated C. difficile infections
PCR-ribotype Toxin genes Number % Cumulative %
018 A+B+ 37 26.4 26.4
017 A–B+ 22 15.7 42.1
001 A+B+ 20 14.3 56.4
014 A+B+ 7 5.0 61.4
112 A+B+ 5 3.6 65.0
002 A+B+ 5 3.6 68.6
130 A+B+CDT+ 4 2.9 71.5
027 A+B+CDT+ 3 2.1 73.6
AB24a A+B+ 3 2.1 75.7
Others 34 24.3 100
A+B+, toxin A-positive, toxin B-positive strain; A–B+, toxin A-negative, toxin B-
positive strain; CDT+, binary toxin-positive strain.
aRibotypes of AB24 are under study and nomenclature was adopted from the
nomenclature system of Kim et al. [17].
TABLE 2. The correlation between the incidence of Clostridium difficile infection (CDI) and defined daily dose (DDD) of
prescribed antibiotics by departments
Department PD GE GS HO NE NR NS PS RM
Spearman’s rho p valueCDI/105 patient-days 134.93 33.21 48.83 79.93 185.77 74.61 101.01 26.10 52.11
DDD/1000 patient-days
Clindamycin 157.4 2.6 3.6 10.6 7.3 25.2 7.2 1.1 2.7 0.783 0.013
Moxifloxacin 172.1 3.9 7.6 17.2 17.4 19.6 12.1 4.9 2.6 0.733 0.025
Fluoroquinolonesa 470.2 110.6 57.6 81.5 176.1 66.5 42.6 34.7 81.2 0.550 0.125
ESC 222.6 132.9 235.1 145.0 165.0 83.3 581.4 275.3 64.5 )0.017 0.966
Cephalosporinsb 333.3 160.1 371.1 173.0 213.6 95.3 604.2 939.2 144.4 )0.050 0.898
BLI 45.5 39.4 25.9 79.4 60.5 55.9 31.7 93.1 48.6 0.000 1.000
Total antibioticsc 1135.1 482.9 632.5 495.1 607.4 271.6 784.5 1187.5 366.9 0.050 0.898
ESC, extended-spectrum cephalosporins; BLI, b-lactam/b-lactamase inhibitors; PD, pulmonary department; GE, gastroenterology; GS, general surgery; HO, haemato-oncology;
NE, nephrology; NR, neurology; NS, neurosurgery; PS, plastic surgery; RM, rheumatology.
aTotal fluoroquinolones included moxifloxacin.
bTotal cephalosporins included extended-spectrum cephalosporins.
cTotal antibiotics included cephalosporins, fluoroquinolones, b-lactam/b-lactamase inhibitors, carbapenems, clindamycin, colistin, glycopeptides, metronidazole, tetracyclines,
trimethoprim/sulphamethoxazole, and linezolid.
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(R = 0.733, p 0.025) (Table 2). The prescription densities of
clindamycin and moxifloxacin in different departments ranged
from 1.0 to 157.4 and 2.6 to 172.1 per 1000 patient-days,
respectively. Use of fluoroquinolones (including moxifloxa-
cin), extended-spectrum cephalosporins, cephalosporins
(including extended-spectrum cephalosporins) or b-lactam/
b-lactamase inhibitors did not show a correlation with the
incidence of CDI: fluoroquinolones (R = 0.550, p 0.125),
extended-spectrum cephalosporins (R = )0.017, p 0.966),
cephalosporins (R = )0.050, p 0.898) or b-lactam/b-lactam-
ase inhibitors (R = 0.000, p 1.000). The total amount of oral
or intravenous antibiotics prescribed in each department did
not correlate with the incidence of CDI either (R = 0.050,
p 0.898), The monthly incidence of CDI varied from 52 to
114 per 100 000 patient-days during the study period [8].
We failed to find correlation between the monthly incidence
of CDI and prescription of clindamycin, moxifloxacin, fluor-
oquinolones, extended-spectrum cephalosporins, cephalospo-
rins, b-lactam/b-lactamase inhibitors and total antibiotics per
month: clindamycin (R = 0.049, p 0.880), moxifloxacin
(R = )0.042, p 0.897), fluoroquinolones (R = )0.042, p 0.898),
extended-spectrum cephalosporin (R = )0.406, p 0.191),
b-lactam/b-lactamase inhibitors (R = )0.098, p 0.762) and
total antibiotics (R = )0.601, p 0.342).
Distribution of PCR-ribotypes over time and by hospital
ward
Fig. 2(a) shows the monthly distribution of the identified rib-
otypes. Ribotype 018 isolates appeared continuously
throughout the year, with an average of 3.08 per month. An
outbreak of CDI associated with ribotype 018 occurred in
seven patients in August 2009. Another large cluster strain
involved ribotype 017 affecting 11 patients during November
and December 2009. Ribotype 001 strains were isolated at a
rate of 1.7 per month, and small outbreaks were suspected
in June and October 2009 and in January 2010.
Fig. 2(b) shows the distribution of ribotypes by hospital
ward. Ribotype 018 appeared in all wards, whereas ribotype
017 appeared mainly in wards 16 and 18, and ribotype 001
in ward 16. The ribotypes of ten isolates from patients with
healthcare-associated CDI, occurring within 2 months of dis-
charge, were identified as hospital-endemic strains. The mean
period from the last discharge to admission for the patients
with HA-CDI was 16.6 days (5–39 days). Five of the patients
developed CDI for the first time, three experienced their
first relapses, and two experienced second or further
relapses.
A histogram of ribotype distribution by departments is
shown in Fig. 2(c). It shows that certain departments were
more likely to harbour endemic strains: ribotype 018 in the
nephrology and general surgery departments (55.0% and
60.0% of all isolates from each department, respectively), rib-
otype 017 in the pulmonary, haemato-oncology and neurol-
ogy departments (29.6%, 30.8% and 50.0%, respectively) and
ribotype 001 in the pulmonary department (37.0%). Of the
11 isolates producing binary toxins, eight (72.7%) were
detected in the neurosurgery department, and ribotype 130
isolates came only from that department. All PCR-ribotype
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FIG. 2. Ribotype distribution of Clostridium difficile isolates over time and hospital location. (a) Monthly distribution of ribotypes, (b) distribution
of ribotypes according to hospital ward, (c) distribution of ribotypes according to admission department; for (a) all the isolates were included,
for (b) and (c) hospital ward or department with more than three isolates were included. H, healthcare-associated C. difficile infection (CDI)
(community onset CDI within 2 months of discharge from hospital); M, medical intensive-care unit; S, surgical intensive-care unit; PD, pulmonary
department; GE, gastroenterology; GS, general surgery; HO, haemato-oncology; ID, infectious diseases; NE, nephrology; NR, neurology; NS,
neurosurgery; PS, plastic surgery; RM, rheumatology.
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027 strains were detected in 1 month, whereas ribotype 130
brought about four episodes in consecutive months in the
neurosurgery department. PCR-ribotype 122, a binary toxin-
producing strain related to ribotype 027 [9], was isolated
from one patient in the neurosurgery department after
13 days of hospitalization.
Comparison of antibiotic resistance in the large-cluster
isolates with other isolates
The cut-off values for resistance to clindamycin and moxi-
floxacin were defined as MIC ‡ 8 mg/L by reference to the
CLSI [19]. We categorized the isolates as large-cluster iso-
lates and other isolates, and compared rates of antibiotic
resistance in the two groups. Antibiotic susceptibility was
tested in 76 out of 79 large-cluster isolates and in 55 out of
61 other isolates. Clindamycin resistance in the large-cluster
isolates reached 92.1%, compared with 38.2% in the other
isolates (p <0.0001), and the frequency of resistance to
moxifloxacin was three-fold higher in the large-cluster iso-
lates than in the other isolates (89.5% and 27.3%, respec-
tively; p <0.0001). There was no significant correlation
between prescription of clindamycin or moxifloxacin in each
department and the rates of resistance of the relevant iso-
lates to clindamycin or moxifloxacin (R = 0.162, p 0.678 and
R = 0.226, p 0.559, respectively).
Discussion
We studied all CDI cases that occurred in our care facility
over 1 year, and characterized the C. difficile isolates. This is
the first prospective surveillance study of CDI in Korea. The
incidence of CDI per 100 000 patient-days during the study
period was 71.6 [8], which was similar to the rate recorded
during high-incidence years in a tertiary-care centre in the
USA before the B1/NAP1/027 strain outbreak [13]. How-
ever, compared with the incidence of 41 per 100 000
patient-days recently reported in a surveillance study in 34
European countries, our rate is high and deserves more local
and national attention [6]. Several hospital-endemic C. difficile
strains were identified, and these made up a large proportion
of all isolates. The diversity index was 27.1% and the pre-
dominant ribotype strain accounted for 26.4% of all cases.
These findings point to simultaneous occurrence of endemic
infections and outbreaks in our hospital.
Ribotype 018, the predominant type in our hospital, was
also found to be prevalent in Italy, where it was associated
with more severe disease [6]. Toxin A-negative ribotype 017
strains were known to be prevalent in East Asia, whereas
their prevalence in Europe and North America was as low
as 0.2–8% [6,10,20–22]. Studies of the outcomes and clinical
manifestations of CDI caused by toxin A-negative toxin
B-positive ribotype 017 strains have reported conflicting
results: some found no difference from other ribotypes
[10,23–25], while others reported more severe disease and
significantly worse outcomes [24,26]. Ribotypes 001 and 014
were reported as prevalent in Europe (16% and 10%, respec-
tively), where they were distributed over a large area [6].
The most common type in Germany, ribotype 001 (70%),
was sixth in southern Scotland and second in Ireland
[18,27,28]. These strains were shown to be resistant to mul-
tiple antibiotics, including moxifloxacin, erythromycin, ceftri-
axone and clindamycin, which could explain the sudden
clonal expansion of ribotype 001 [27]. Ribotype 014 is
almost identical to ribotype 020, and some studies represent
them as 014/020 [6]. PCR-ribotype 014 was reported as less
prevalent than 001, and with less frequent resistance to anti-
biotics [27]. We identified three C. difficile ribotype 027 iso-
lates and sequencing of tcdC in these isolates revealed
mutations that were specific to the NAP1/027 strains. How-
ever, as all three isolates were sensitive to moxifloxacin
(range of MICs, 1–2 mg/L), they were considered to resem-
ble ‘historical’ 027 strains [5]. Because they were also sus-
ceptible to clindamycin (data not shown), we believe that
they did not have a selective advantage over the endemic
large-cluster isolates, and therefore did not create a large
outbreak or persist in the hospital.
There was a seven-fold difference between the lowest and
the highest CDI incidence in different departments. The
most probable cause of this difference is the amount of anti-
biotics prescribed, although the spread of C. difficile through
environmental contamination or the hands of healthcare per-
sonnel could also be a factor. Our results demonstrate a
correlation between the incidence of CDI and the use of
clindamycin or moxifloxacin in all departments. Previous
reports indicated that extended-spectrum cephalosporins
and clindamycin were most frequently associated with higher
rates of CDI [1,3]. It is possible that despite the hospital-
wide prescription of extended-spectrum cephalosporins,
b-lactam/b-lactamase inhibitors and fluoroquinolones, the
skewed use of clindamycin and moxifloxacin (mostly in the
pulmonary department) led to a statistically significant result.
Nevertheless, considering the high rates of resistance of
large-cluster isolates to clindamycin and moxifloxacin, in
addition to the significant correlation between these antibiot-
ics and CDI incidence in this study, it is more likely that
clindamycin and moxifloxacin were imposing strong selective
pressures on C. difficile, as shown elsewhere [5,26]. A recent
report described how a hospital outbreak of resistant
C. difficile was successfully controlled by restricting the use of
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fluoroquinolone [29], showing that it is necessary to imple-
ment antibiotic stewardship and infection control practices
to reduce the incidence of HA-CDI.
There are two potential limitations to our study. Because
CDI was diagnosed by stool culture or toxin assay only when
requested, the incidence of CDI may be underestimated. Sec-
ond, although the CDI rate was very high in the nephrology
department, that department did not consume significantly
larger amounts of clindamycin, moxifloxacin, extended-spec-
trum cephalosporins or total antibiotics. In addition to antibi-
otics, other risk factors such as age, co-morbidity and hospital
admission could strongly influence the incidence of CDI. Dif-
ferences of age, co-morbidities and other risk factors between
patients in the different departments are to be expected;
however, they were not evaluated in this study.
This is the first prospective surveillance study of CDI in
Korea, and it demonstrates that CDI is an important
hospital-acquired infection. Our findings stress the importance
of implementing a country-wide CDI surveillance and of
introducing infection control measures.
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